R R

What Is Remicade?

Remicade is a prescription biologic medication containing infliximab, a monoclonal antibody that blocks tumor necrosis factor alpha, or TNF-alpha. It is used to treat selected inflammatory and autoimmune conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Remicade is administered by intravenous infusion under medical supervision. It can reduce inflammation, relieve symptoms, and help maintain disease control in eligible patients. Because it suppresses part of the immune response, Remicade carries boxed warnings for serious infections and malignancies, including lymphoma.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Remicade?

Remicade is a prescription biologic medication containing infliximab, a monoclonal antibody that blocks tumor necrosis factor alpha, or TNF-alpha. It is used to treat selected inflammatory and autoimmune conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Remicade is administered by intravenous infusion under medical supervision. It can reduce inflammation, relieve symptoms, and help maintain disease control in eligible patients. Because it suppresses part of the immune response, Remicade carries boxed warnings for serious infections and malignancies, including lymphoma.

read more about remicade ...

Copy this HTML:

Copy HTML Copied!

How Does Remicade Work?

Remicade binds to TNF-alpha, a signaling protein that contributes to inflammation and immune system activity. In certain autoimmune diseases, excessive TNF-alpha signaling promotes tissue inflammation and damage. Infliximab blocks the activity of soluble and membrane-bound TNF-alpha, reducing inflammatory processes involved in joint, intestinal, and skin disorders. This can improve symptoms and help prevent disease-related complications. Remicade does not permanently cure autoimmune diseases, and symptoms may return after treatment stops. Blocking TNF-alpha can also weaken the body's ability to control infections, including tuberculosis and certain fungal infections.

What Conditions Does Remicade Treat?

Remicade is approved for moderately to severely active Crohn's disease and ulcerative colitis in eligible adults and children aged six years and older. Adult indications also include moderately to severely active rheumatoid arthritis, active ankylosing spondylitis, active psoriatic arthritis, and chronic severe plaque psoriasis in specified patients. For rheumatoid arthritis, Remicade is prescribed with methotrexate. Treatment eligibility depends on the diagnosis, disease severity, previous therapies, and medical history. Patients must be evaluated for tuberculosis and hepatitis B before treatment because TNF-alpha inhibition can reactivate certain infections.

How Is Remicade Administered?

Remicade is administered through intravenous infusion by a healthcare professional. For Crohn's disease and ulcerative colitis, treatment commonly begins with 5 mg/kg at weeks zero, two, and six, followed by maintenance infusions every eight weeks. Rheumatoid arthritis generally begins with 3 mg/kg on the same induction schedule, followed by maintenance dosing every eight weeks alongside methotrexate. Other conditions have separate dosing schedules. Each infusion is administered over at least two hours, with monitoring for infusion reactions. Clinicians assess infection status, treatment response, and laboratory findings throughout therapy. Patients should not administer Remicade themselves.

What Are the Side Effects and Warnings of Remicade?

Common adverse effects include upper respiratory infections, headache, abdominal discomfort, nausea, and infusion-related reactions. Remicade carries boxed warnings for serious infections, including tuberculosis, invasive fungal infections, and bacterial infections, as well as lymphoma and other malignancies. Rare cases of hepatosplenic T-cell lymphoma have occurred, particularly in young patients with inflammatory bowel disease receiving certain immunosuppressive treatments. Other serious risks include hepatitis B reactivation, liver injury, worsening heart failure, and demyelinating disorders. Patients should report persistent fever, cough, unexplained weight loss, unusual bruising, breathing difficulties, or neurological changes promptly.

Common Questions About Remicade

Is Remicade the same as infliximab?

Yes. Remicade contains infliximab, a TNF-alpha inhibitor used to treat certain inflammatory and autoimmune diseases.

Can Remicade treat Crohn's disease?

Yes. Remicade is approved for moderately to severely active Crohn's disease in eligible adults and children aged six years and older.

How often are Remicade infusions given?

Many treatment regimens begin with infusions at weeks zero, two, and six, followed by maintenance treatment every eight weeks. Certain conditions require different schedules.

Does Remicade increase infection risk?

Yes. Remicade suppresses part of the immune response and carries a boxed warning for serious infections, including tuberculosis and invasive fungal infections.

References

DailyMed - REMICADE (infliximab) injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257. Date Accessed November 3, 2026.

Infliximab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548203/. Date Accessed November 3, 2026.

Infliximab. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK500021/. Date Accessed November 3, 2026.

Infliximab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a604023.html. Date Accessed November 3, 2026.

Remicade. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/remicade. Date Accessed November 3, 2026.